| Novo
Nordisk to acquire Inversago Pharma to develop new therapies
for people living with obesity, diabetes and other serious
metabolic diseases | 2023.08.10 |
| Health
Canada approves Alhemo™ (concizumab injection) for
the treatment of patients living with hemophilia A with FVIII
inhibitors | 2023.07.27 |
| Health Canada approves Alhemo™, the
first subcutaneous prophylactic treatment for people living
with hemophilia B with inhibitors |
2023.04.17 |
| Aspect
Biosystems and Novo Nordisk enter partnership to develop
bioprinted tissue therapeutics for diabetes and
obesity | 2023.04.12 |